Advances in therapy for hepatitis C infection

Microbes and Infection

Volumn 4, Issue 12, 2002, Pages 1237-1246

  Zein, Claudia O ^a   Zein, Nizar N ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hepatitis C; Therapy; Viral hepatitis

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ALOPECIA; AMENORRHEA; AMNESIA; ANEMIA; ANOREXIA; ARTHRITIS; BRAIN DISEASE; CARDIOMYOPATHY; CHILL; COMORBIDITY; CONFUSION; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG FORMULATION; DRUG MONITORING; DRUG RESPONSE; DRUG SCREENING; DRY SKIN; FATIGUE; FEVER; GYNECOMASTIA; HALF LIFE TIME; HEADACHE; HEART ARRHYTHMIA; HEPATITIS C; HEPATITIS C VIRUS; HYPERTENSION; IMPOTENCE; JAUNDICE; LEG CRAMP; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FAILURE; MUSCLE WEAKNESS; MYALGIA; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; RASH; REACTIVE DEPRESSION; RESPIRATORY TRACT DISEASE; REVIEW; THROMBOCYTOPENIA; THYROID DISEASE; URINARY TRACT DISEASE; UTERUS BLEEDING; VISUAL DISORDER;

ANTIVIRAL AGENTS; BIOMEDICAL RESEARCH; HEPATITIS C; HERPES SIMPLEX; HUMANS; INTERFERONS;

HEPATITIS C VIRUS;

EID: 0036815957     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(02)01651-9     Document Type: Review

References (46)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepatol. 6:1999;35-47.
2. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., Margolis H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New Engl. J. M. 341:1999;556-562.
3. Hoofnagle J.H., Mullen K.D., Jones D.B., Rustgi V., Di Bisceglie A., Peters M., Waggoner J.G., Park Y., Jones E.A. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. New Engl. J. M. 315:1986;1575-1578.
4. Di Bisceglie A.M., Martin P., Kassianides C., Lisker-Melman M., Murray L., Waggoner J., Goodman Z., Banks S.M., Hoofnagle J.H. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. New Engl. J. M. 321:1989;1506-1510.
5. Davis G.L., Balart L.A., Schiff E.R., Lindsay K., Bodenheimer Jr H.C., Perrillo R.P., Carey W., Jacobson I.M., Payne J., Dienstag J.L., Van Thiel D.H., Tamburro C., Lefkowitch J., Albrecht J., Meschievitz C., Ortego T.J., Gibas A. New Engl. J. M. 321:1989;1501-1506.
6. Carithers Jr R.L., Emerson S.S. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology. 26:(Suppl 1):1997;83S-88S.
7. Patterson J.L., Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev. Infect. Dis. 12:1990;1139-1146.
8. Dusheiko G., Main J., Thomas H., Reichard O., Lee C., Dhillon A., Rassam S., Fryden A., Reesink H., Bassendine M., Norkrans G., Cuypers T., Lelie N., Telfer P., Watson J., Weegink C., Sillikens P., Weiland O. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J. Hepatol. 25:1996;591-598.
9. Schalm S.W., Hansen B.E., Chemello L., Bellobuono A., Brouwer J.T., Weiland O., Cavalletto L., Schvarcz R., Ideo G., Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J. Hepatol. 26:1997;961-966.
10. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New Engl. J. M. 339:1998;1485-1492.
11. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., Shiffman M.L., Zeuzem S., Craxi A., Ling M.H., Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. New Engl. J. M. 339:1998;1493-1499.
12. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 282:1998;103-107.
13. Zeuzem S., Feinman S.V., Rasenack J., Heathcote E.J., Lai M.Y., Gane E., O'Grady J., Reichen J., Diago M., Lin A., Hoffman J., Brunda M.J. Peginterferon alfa-2a in patients with chronic hepatitis C. New Engl. J. M. 343:2000;1666-1672.
14. Heathcote E.J., Shiffman M.L., Cooksley W.G., Dusheiko G.M., Lee S.S., Balart L., Reindollar R., Reddy R.K., Wright T.L., Lin A., Hoffman J., De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New Engl. J. M. 343:2000;1673-1680.
15. Fried M.W., Shiffman M.L., Reddy R.K., Smith C., Marino G., Goncales Jr F., Haeussinger D., Diago M., Carosi G., Zarski J.-P., Hoffman J., Yu J. Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: efficacy and safety results from a phase III, randomized actively-controlled, multicenter study (abstract). Gastroenterology. 120:2001;A55.
16. Gaglio P.J., Regenstein F.G., Vlacos M.N., Bartholomew D., Randazzo P. Pegylated interferon and ribavirin for the treatment of HCV infected patients who failed previous interferon therapy (abstract). Gastroenterology. 120:2001;A384.
17. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 26:(Suppl 1):1997;2S-10S.
18. European Association for the Study of the Liver. EASL International Consensus Conference on Hepatitis C. Paris, 26-28 February 1999, Consensus Statement. J. Hepatol. 30:1999;956-961.
19. Liang T.J. Combination therapy for hepatitis C infection. New Engl. J. M. 339:1998;1549-1550.
20. Poynard T., McHutchison J., Goodman Z., Ling M.H., Albrecht J. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 31:2000;211-218.
21. Reddy K.R., Hoofnagle J.H., Tong M.J., Lee W.M., Pockros P., Heathcote E.J., Albert D., Joh T. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology. 30:1999;787-793.
22. Lau D.T., Kleiner D.E., Ghany M.G., Park Y., Schmid P., Hoofnagle J.H. Ten-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 28:1998;1121-1127.
23. Marcellin P., Boyer N., Gervais A., Martinot M., Pouteau M., Castelnau C., Kilani A., Areias J., Auperin A., Benhamou J.P., Degott C., Erlinger S. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann. Intern. M. 127:1997;875-881.
24. Shiffman M.L., Hofmann C.M., Contos M.J., Luketic V.A., Sanyal A.J., Sterling R.K., Ferreira-Gonzalez A., Mills A.S., Garret C. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology. 117:1999;1164-1172.
25. Poynard T., Moussalli J., Ratziu V., Regimbeau C., Opolon P. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin. Liver Dis. 3:1999;869-881.
26. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., Inoue O., Yano M., Tanaka M., Fujiyama S., Nishiguchi S., Kuroki T., Imazeki F., Yokosuka O., Kinoyama S., Yamada G., Omata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann. Intern. M. 131:1999;174-181.
27. Ikeda K., Arase Y., Saitoh S., Kobayashi M., Suzuki Y., Suzuki F., Tsubota A., Chayama K., Murashima N., Kumada H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 32:2000;228-232.
28. Bonkovsky H.L., Woolley J.M. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 29:1999;264-270.
29. Ware Jr J.E., Bayliss M.S., Mannocchia M., Davis G.L. Heath-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology. 30:1999;550-555.
30. Beltrami E.M., Williams I.T., Shapiro C.N., Chamberland M.E. Risk and management of blood-borne infections in health care workers. Clin. Microbiol. Rev. 13:2000;385-407.
31. Alter M.J. Occupational exposure to hepatitis C virus: a dilemma. Infect. Control Hosp. Epidemiol. 15:1994;742-744.
32. Jaeckel E.C.M., Wedemeyer H., Santantonio T., Mayer J., Zankel M., Pastore G., Dietrich M., Trautwein C., Manns M.P., the German Acute Hepatitis C. Therapy Group, Treatment of acute hepatitis C with interferon alfa-2B. New Engl. J. M. 345:2001;1452-1457.
33. Marcellin P., Levy S., Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology. 26:(Suppl 1):1997;133S-136S.
34. Fattovich G., Giustina G., Degos F., Diodati G., Tremolada F., Nevens F., Almasio P., Solinas A., Brouwer J.T., Thomas H., Realdi G., Corrocher R., Schalm S.W. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J. Hepatol. 27:1997;201-205.
35. Pascual M., Perrin L., Giostra E., Schifferli J.A. Hepatitis C virus in patients with cryoglobulinemia type II. J. Infect. Dis. 162:1990;569-570.
36. Chin C., Zein N.N. Extrahepatic syndromes associated with hepatitis C infection. Gastroenterol. Int. 11:1998;26-35.
37. Misiani R., Bellavita P., Fenili D., Vicari O., Marchesi D., Sironi P.L., Zilio P., Vernocchi A., Massazza M., Vendramin G., Tanzi E., Zanetti A. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. New Engl. J. M. 330:1994;751-756.
38. Davis G.L., Rodrigue J.R. Treatment of chronic hepatitis C in active drug users. New Engl. J. M. 345:2001;215-217.
39. Edlin B.R., Seal K.H., Lorvick J., Kral A.H., Ciccarone D.H., Moore L.D., Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users. New Engl. J. M. 345:2001;211-215.
40. Wedemeyer H., Tegtmeyer B., Tillmann H.L., Cornberg M., Schueler A., Liermann H., Trautwein C., Manns M.P. Impact of HBV coinfection on hepatitis C virus infection: analysis of 3054 anti HCV-positive patients (abstract). J. Hepatol. 34:(Suppl 1):2001;4-5.
41. Weltman M.D., Brotodihardjo A., Crewe E.B., Farrell G.C., Bilous M., Grierson J.M., Liddle C. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J. Viral Hepatol. 2:1995;39-45.
42. Chiaramonte M., Stroffolini T., Vian A., Stazi M.A., Floreani A., Lorenzoni U., Lobello S., Farinati F., Naccarato R. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer. 85:1999;2132-2137.
43. Sagnelli E., Coppola N., Scolastico C., Mogavero A.R., Filippini P., Piccinino F. HCV genotype and 'silent' HBV coinfection: two main risk factors for a more severe liver disease. J. Med. Virol. 64:2001;350-355.
44. Koike K., Nakamura Y., Kobayashi M., Takada S., Urashima T., Saigo K., Kobayashi S., Isono K., Hayashi I., Fujii A. Hepatitis B virus DNA integration frequently observed in the hepatocellular carcinoma DNA of the hepatitis C virus-infected patients. Int. J. Oncol. 8:1996;781-784.
45. Bortolotti F., Giacchino R., Vajro P., Barbera C., Crivellaro C., Alberti A., Nebbia G., Zancan L., De Moliner L., Bertolini A., Balli F., Callea F. Recombinant interferon-alfa therapy in children with chronic hepatitis C. Hepatology. 22:1995;1623-1627.
46. Zein N.N. Experimental and emerging therapies for chronic hepatitis C virus infection. Expert Opin. Investig. Drugs. 10:2001;1457-1469.